Voices
Xiuning Le
Xiuning Le/X

Xiuning Le: FDA Granted Accelerated Approval for Sevabertinib for HER2-Mutant NSCLC 

Xiuning Le, Associate Professor, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared a post on LinkedIn:

“FDA granted accelerated approval for sevabertinib for HER2-mutant NSCLC
In previously treated patients without prior anti-HER2 targeted therapies (SOHO-01, cohort D, non-SQC NSCLC with HER2 TKD mutations)

  •  ORR 71%
  •  PFS 9.2 months
  •  most common side effect is diarrhea

Deep gratitude to patients and families who contributed to advancing Science and Medicine, and we thank our colleagues and pharma partners for making this possible.”

More posts featuring Xiuning Le.

cancer OncoDaily Oncology Xiuning Le